Quark Pharmaceuticals Secures $10,000,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=216c10cc-9393-46fd-9fac-25fad8ae4be1&Preview=1 -
Date
6/10/2010 -
Company Name
Quark Pharmaceuticals -
Mailing Address
6501 Dumbarton Circle Fremont, CA 94555 -
Company Description
Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark’s RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA locally and systemically to organs including the eye, ear, kidney, lung, spinal cord and bone marrow. -
Website
http://www.quarkpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$10,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Quark Pharmaceuticals will use the funds to advance its RNAi drug pipeline, which has the largest number of clinical-stage siRNA therapeutic programs in the industry. The Company’s pipeline candidates are currently being evaluated in five different clinical trials. -
M&A Terms
-
Venture Investor
SBI Holding Inc. -
Venture Investor
SBI Holding Inc.
